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Abstract
Objective: Hepatocellular carcinoma (HCC) is difficult to manage due to the high frequency of post-surgical recurrence.
Early detection of the HCC recurrence after liver resection is important in making further therapeutic options, such as
salvage liver transplantation. In this study, we utilized microRNA expression profiling to assess the risk of HCC recurrence
after liver resection.
Methods: We examined microRNA expression profiling in paired tumor and non-tumor liver tissues from 73 HCC patients
who satisfied the Milan Criteria. We constructed prediction models of recurrence-free survival using the Cox proportional
hazard model and principal component analysis. The prediction efficiency was assessed by the leave-one-out cross-
validation method, and the time-averaged area under the ROC curve (ta-AUROC).
Results: The univariate Cox analysis identified 13 and 56 recurrence-related microRNAs in the tumor and non-tumor tissues,
such as miR-96. The number of recurrence-related microRNAs was significantly larger in the non-tumor-derived microRNAs
(N-miRs) than in the tumor-derived microRNAs (T-miRs, P,0.0001). The best ta-AUROC using the whole dataset, T-miRs, N-
miRs, and clinicopathological dataset were 0.8281, 0.7530, 0.7152, and 0.6835, respectively. The recurrence-free survival
curve of the low-risk group stratified by the best model was significantly better than that of the high-risk group (Log-rank:
P=0.00029). The T-miRs tend to predict early recurrence better than late recurrence, whereas N-miRs tend to predict late
recurrence better (P,0.0001). This finding supports the concept of early recurrence by the dissemination of primary tumor
cells and multicentric late recurrence by the ‘field effect’.
Conclusion: microRNA profiling can predict HCC recurrence in Milan criteria cases.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignancies worldwide, and is the fourth most common cause of
mortality [1,2]. In addition, its incidence is increasing in many
countries [3,4]. HCC is difficult to manage, as compared with
other common malignant diseases due to the high percentage of
co-existing liver cirrhosis. The impaired liver function caused by
liver cirrhosis often restricts treatment options, even for early
HCC. Liver resection (LR) and orthotopic liver transplantation
(OLT) are considered as the only two potentially curative
treatment options for HCC. Currently, the Milan Criteria (i.e.,
solitary tumor #5 cm, or 2 or 3 tumors #3 cm) [5] are widely
accepted as the selection Criteria for OLT in HCC patients. For
HCC patients with severe liver cirrhosis (Child-Pugh C), OLT is
considered the first-line treatment. In these cases, LR is
contraindicated because of impaired liver function. In contrast,
there has been an intense debate about which treatment option of
LR or OLT is the optimal initial treatment for HCC patients with
no to mild liver cirrhosis (Child-Pugh A/B). Some authors have
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16435recommended OLT as the first-line treatment for HCC fulfilling
the Milan Criteria given the lower tumor recurrence rate after
OLT[6,7]. On the other hand, due to the shortage of donor
organs, many liver transplant centers choose LR for HCC patients
with Child-Pugh A/B, and who satisfy the Milan Criteria.
Therefore, the strategy of a primary LR and salvage transplan-
tation for intrahepatic HCC recurrence is a reasonable tactic for
early resectable HCC with preserved liver function. In this
strategy, it is important to predict recurrent tumors for selecting
the follow-up protocol of patients after LR.
In our previous reports, we screened prognostic factors from
various clinical features, and found that co-existing cirrhosis
correlated with the outcomes of HCC cases within the Milan
Criteria[8]. Moreover, utilizing clinical factors, we also deter-
mined a safe expanded selection criteria for the indications of
living donor liver transplantation in HCC patients beyond the
Milan Criteria[9]. To obtain better-optimized stratification criteria
and a more accurate prediction of recurrence, biological
information and biomarkers derived from ‘‘OMICS’’ approaches,
e.g., transcriptomics and proteomics, will be powerful tools.
MicroRNAs are a class of small non-coding RNAs [19–23
nucleotides (nt)] that have been found in animal and plant cells. As
of today, 1049 human microRNAs are registered in the miRBase
database (Release 16, September, 2010)[10–13]. MicroRNA genes
are transcribed as non-coding transcripts, and are processed
through a series of sequential steps involving the RNase III
enzymes, Drosha and Dicer. The processed microRNAs are finally
incorporated into the RNA-induced silencing complex (RISC) to
mediate the target mRNA repression of translation and/or
degradation. It has been reported that microRNAs are involved
in physiological and pathological functions, such as the regulation
of developmental timing and pattern formation[14], the restriction
of differentiation potential[15], chromatin rearrangements[16],
and carcinogenesis[17]. Many of the mechanistic details still
remain unknown.
In the last decade, gene expression profiling has been utilized to
classify the type of HCC and to predict the recurrence and survival
of HCC patients [18–21]. Moreover, recent microarray technol-
ogy has been utilized to analyze a comprehensive microRNA
expression profiling of HCC [22,23]. However, a microarray-
based prediction of HCC recurrence, especially for early HCC
patients, have not been reported.
Previously, we developed a highly sensitive platforms for both
mRNA and microRNA expression profiling [24]. Our ultimate
goal is to apply microarray technology into the clinical field.
Thus, we previously evaluated a microRNA-microarray platform
as a future IVDMIA (in vitro diagnostic multivariate index assay)
device using analytical procedures recommended by the Micro-
array quality control (MAQC) project [25]. In this study, we
examined whether microRNA microarray technology can predict
recurrent HCC after LR for patients who satisfying the Milan
Criteria.
Figure 1. Flow chart of the prediction model construction and validation. To establish prediction models, the leave-one-out cross-validation
method (LOOCV), principal component analysis (PCA), and Cox proportional hazard (CoxPH) models were used. In each LOOCV cycle, the variables of
the training datasets or principal component (PC) dataset were prioritized by univariate CoxPH model analysis. Next, multivariate CoxPH models were
developed using 1,30 top-ranked variables, and 30 predicted recurrence-free survival curves were the output for a test dataset. After 73 LOOCV
cycles, 73630 predicted recurrence-free survival curves were generated. For each number of variables used, the time-averaged AUROC was calculated
using a set of 73 predicted survival curves. Finally, a model with the best time-averaged AUROC was selected.
doi:10.1371/journal.pone.0016435.g001
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Patients
Between January, 1997 and March, 2007, 639 patients with
HCC underwent hepatic resection as a primary curative
treatment. Among these patients, 73 patients satisfied the following
patient enrollment criteria; 1) no preoperative therapy, 2) within
the Milan Criteria, 3) with Child-Pugh A-B level cirrhosis, 4) no or
minimum vessel invasion (pathological Vp0-2 and Vv0-1 accord-
ing to the General Rules for the Clinical and Pathological Study of
Primary Liver Cancer, the 4th edition [26]), 5) availability of
frozen paired tumor and non-tumor liver tissues, and 6) the quality
of extracted RNA was good enough for microarray analysis. This
study was approved by the Institutional Review Board of School of
Medicine and Kyoto University Hospital, and the Human Tissue
Samples Ethics Committee for R&D, Toray Ind., Inc. All patients
gave their written informed consent to the sample collection and
analyses described in the present study, in agreement with the
Declaration of Helsinki.
RNA extraction
Tumor and non-tumor tissues were obtained and frozen in
liquid nitrogen immediately after hepatic resection, and were
stored in liquid nitrogen until RNA extraction. The total RNA
samples were extracted by a phenol-chloroform RNA extraction
method (Trizol; Invitrogen, Carlsbad, Calif., USA). The quality of
the purified total RNAs was analyzed by a Bioanalyzer 2100
(Agilent Technologies, Palo Alto, Calif., USA). The criteria for the
use of a sample was that the 18s and 28s ribosomal RNA peaks
were twice or more higher than the other peaks, as previously
described [27]. The RNA Integrity Numbers (RIN) of Bioanalyzer
software for all samples was more than 5.
MicroRNA expression profiling
We utilized Toray’s 3D-Gene
TM human microRNA chips
(miRBase version 12) for microRNA expression profiling. The
reproducibility and comparability to Taqman RT-PCR, and the
experimental procedures of Toray’s microarray, were described
previously [25]. Briefly, for each patient, 500 ng of total RNA
derived from both tumor and non-tumor samples were labeled
using miRCURY LNA
TM microRNA Power Labeling Kits Hy5
(Exiqon, Vedbaek, Denmark). The labeled samples were individ-
ually hybridized onto the DNA chip surface, and were incubated at
42uC for 16 hours. The washed and dried DNA chip in an ozone-
free environment was scanned using a ProScanArray
TM microarray
scanner (PerkinElmer Inc. Waltham, MA). The obtained micro-
array images were analyzed using Genepix Pro
TM 4.0 software
(MolecularDevice, Sunnyvale,CA). Inthisstudy,the medianvalues
of the foreground signal minus the local background were
represented as the feature intensities. The microRNA expression
profile of all samples was illustrated as a heatmap in Figure S1.
Data analyses procedures
In this study, the recurrence-free survival was defined as the time
between the operationdate andthedatewhen therecurrenttumor/
tumors were identified. The clinical dataset consists of 63
clinicopathological information points (Table S1). All data obtained
from the microarray experiments were normalized by a quantile
normalization method [28], and then were filtered (75 percentile of
miR expression .6 in log2 scale). Thus, 193 microRNAs were
selected, and finally 579 data points (579=19363, T-miR, N-miR,
and T/N ratio) for each patient were used for further prediction
model construction. The modelconstruction procedure is illustrated
in a flow chart (Figure 1). All statistical analyses and prediction
model construction were performed using Matlab 2010a software
(Mathworks, Natick, MA, USA). The detailed data process
procedures are described in a supplemental file. In this study, p-
values less than 0.05 were considered as statistically significant. All
microRNA microarray data were registered into NCBI’s Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/projects/geo/). The accession numbers are GSE21362 for
series IDs, and GSM533698,533843 for sample IDs.
Results
Patients’ characteristics
Table 1 summarizes the clinicopathological characteristics of
the patients. All patients were treated with curative surgical liver
resection. The mean recurrence-free survival of the complete cases
(n=45) was 618 days (standard deviation: 517 days). The mean
follow-up periods of the censored cases (n=28) was 1902 days.
Table 1. Clinical Features of 73 HCC patients within Milan
Criteria and Univariate Cox Proportional Hazard Model.
Cox proportional hazard
model
Clinical features hazard ratio p-value
Age mean, range
65.8 (40–88) 0.981 0.228
Gender
female 19 1.077 0.825
male 54
Tumor size
(Max diameter)
mean6SD
3.261.0 0.833 0.235
Child-Pugh
classification
A 69 1.924 0.277
B4
Cirrhosis
(-) 36 1.246 0.463
(+)3 7
Tumor Grade
well 21 0.982 0.938
moderate 45
poor 7
T factor
T1 7 1.692 0.0131
T2 51
T3 13
T4 2
HBV antigen
(-) 61 2.033 0.0490
(+)1 2
HCV antibody
(-) 22 1.119 0.734
(+)5 1
Tumor Grade and Tumor factor are recorded according to the General Rules for
the Clinical and Pathological Study of Primary Liver Cancer (26).
doi:10.1371/journal.pone.0016435.t001
MicroRNA Profile Predicts Recurrence of HCC
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16435Among the 73 patients, 45 had recurrent tumors. The types of
initial recurrences were intrahepatic, extrahepatic, and both for
41, 2, and 2 patients, respectively. According to univariate Cox
proportional hazard model (CoxPH) analysis, T-factor and HBV
infection are significantly associated with a shorter recurrent-free
survival (P=0.0131 and 0.0490, respectively).
Recurrence-related microRNA signature
As the first step in this analysis, we utilized univariate CoxPH to
identify recurrence-related microRNAs (Table 2). Interestingly,
most of the identified tumor-derived microRNAs (T-miRs) were
negatively associated with HCC recurrence, which suggests that
tumor-suppressor microRNAs are down-regulated in tumor tissues.
On the other hand, most of the identified non-tumor-derived
microRNAs (N-miRs), which are ranked in the top-20, were
positively associated with HCC recurrence, which indicated that
oncogenic microRNAs are predominantly up-regulated in non-
tumor tissues. In addition, the number of miRs significantly
correlated with HCC recurrence was larger in non-tumor tissues
than in tumor tissues (Fisher’s exact test: p,0.0001). As the second
step, we applied principal component analysis (PCA) to the
univariate CoxPH analysis. The five principal components (PCs)
of the microRNA expression profile were significantly correlated to
the recurrence-free survival of HCC (Table 3). To show the clinical
significance of each PC, the correlated clinical features of each PC
are also listed in Table 3. For example, PC3 is a HBV and AFP
related PC, and PC16 is a T-factor related one. A 3-dimentional
scatter plot shows that the top 3 ranked PCs correlated to the
recurrence-free survival of HCC patients (Figure 2).
Constructing prediction models of HCC recurrence-free
survival
The prediction model was constructed by multivariate CoxPH
models with leave-one-out cross-validation method (Figure 1). The
accuracy of each prediction was evaluated by a time-averaged
AUROC (AUROC) between 6 months and 5 years. The
AUROC changes depending upon the sample tissues, inclusion
or exclusion of PCA, the number of variables used for constructing
prediction models. Among the various conditions, the best
AUROC (=0.8281) was achieved when the model was
constructed using top-12 PCs data generated from an integrated
dataset consisting of T-miRs and N-miRs, and T/N ratios
(Figure 3). Figure 4 shows the change of AUROCs for different
time points between 6 months and 5 years after LR. This model
can predict early recurrences better (the best AUROC=0.9276 at
1 year after LR) than late recurrences. Next, according to this
prediction model, the 73 cases were stratified into Low- (n=37)
and High-risk (n=36) groups. Consequently, the Kaplan-Meier
recurrence-free survival curve of the Low-risk group was
significantly better than the High-risk group (Figure 5, Wilcoxon
test: p=0.00006, log-rank test: p=0.00029).
The best prediction models generated from only the clinical
data (AUROC=0.6835), T-miRs data (AUROC=0.7152), and
N-miRs data (AUROC=0.7530) were obtained when 2 PCs, 6
Table 2. Recurrence-related microRNAs.
Recurrence-related microRNAs in tumor tissues
Recurrence-related microRNAs in non-tumor tissues (Top 20
out of 56 significant miRs)
Rank microRNA hazard ratio miR-type p-value FDR Rank microRNA hazard ratio miR-type p-value FDR
1 miR-100 0.5170 Ts-miR ,0.0001 0.011 1 miR-27a 7.4696 OncomiR ,0.0001 0.004
2 miR-99a 0.6318 Ts-miR 0.0006 0.035 2 miR-24 11.5691 OncomiR 0.0001 0.004
3 miR-99b 0.6087 Ts-miR 0.0013 0.040 3 miR-96 1.4868 OncomiR 0.0002 0.003
4 miR-125b 0.8062 Ts-miR 0.0028 0.048 4 miR-21 1.6847 OncomiR 0.0004 0.006
5 miR-378 0.6339 Ts-miR 0.0043 0.055 5 miR-18a 1.9046 OncomiR 0.0007 0.007
6 miR-129-5p 0.6888 Ts-miR 0.0075 0.083 6 miR-23a 5.5879 OncomiR 0.0010 0.007
7 miR-125a-5p 0.7441 Ts-miR 0.0089 0.080 7 miR-18b 1.6114 OncomiR 0.0013 0.007
8 miR-497 0.7737 Ts-miR 0.0123 0.090 8 miR-142-3p 1.4802 OncomiR 0.0018 0.007
9 miR-22 0.5470 Ts-miR 0.0141 0.085 9 miR-362-3p 1.4718 OncomiR 0.0020 0.006
10 miR-140-3p 0.5603 Ts-miR 0.0306 0.208 10 miR-1202 0.7592 Ts-miR 0.0021 0.006
11 miR-145 0.7531 Ts-miR 0.0341 0.213 11 let-7e 3.3158 OncomiR 0.0025 0.004
12 miR-221 1.4608 OncomiR 0.0441 0.266 12 let-7f 5.6499 OncomiR 0.0039 0.009
13 miR-195 0.7803 Ts-miR 0.0487 0.262 13 miR-191 7.4922 OncomiR 0.0047 0.011
14 miR-107 6.0708 OncomiR 0.0057 0.014
15 miR-148a 0.5922 Ts-miR 0.0061 0.013
16 miR-222 1.5374 OncomiR 0.0077 0.013
17 miR-103 5.5941 OncomiR 0.0086 0.012
18 miR-126* 2.2102 OncomiR 0.0087 0.012
19 miR-425 2.1610 OncomiR 0.0089 0.012
20 miR-378 0.6406 Ts-miR 0.0090 0.011
This table lists hazard ratio and p-value calculated by an univariate Cox’s propotional hazard model for each microRNA. MicroRNAs which hazard ratio is greater than 1
were correlated with frequent recurrence, and are potential oncomiRs. In contrast, microRNAs with hazard ratio less than 1 were associated with good recurrence-free
survivals, and would be a tumor-suppressor miRs (Ts-miR). The number (=56) of recurrence-related microRNAs in non-tumor tissues is significantly larger than that
(=13) in tumor tissues (Fisher’s exact t-test: p,0.00001). False discovery rate (FDR) were estimated by permutation analysis.
doi:10.1371/journal.pone.0016435.t002
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prediction model predicts recurrences significantly better than
these three models (paired t-test: p,0.00001). In addition, the
AUROC of the N-miRs dataset was also significantly higher than
that of T-miRs dataset. As shown in Figure 4, the AUROCs of the
T-miRs models gradually decreased over the time course between
6 months and 5 years (Pearson’s p-value ,0.0001), which indicates
that the T-miRs can predict early recurrences better than late
recurrences. In contrast, the AUROCs of the N-miR models
gradually elevated, which suggests that N-miRs can predict late
recurrences better than early recurrences (Pearson’s p-value
,0.0001).
Contribution analysis of microRNAs in the best prediction
model
The best overall model was constructed with the PCA and
CoxPH model. Since the coefficients of the CoxPH model were for
PCs not for individual microRNAs, it is difficult to determine how
much each microRNA contributes to this prediction model. In this
study, we combine the coefficients of the PCA and CoxPH, and
converted them to a hazard ratio formula by PC values into
individual microRNAs expression values. As shown in the
supplemental Description S1, the coefficient of the i-th microRNA
can be expressed as
P n
j
bjCji, where n, bj, and Cji represent the
number of PCs, the beta value of the j-th PC, and the coefficient of
the i-th microRNA in the j-th PC, respectively. Table 4 shows the
top-20 contributory microRNAs or Tumor/Non-tumor ratios (T/
N ratios) that are positively and negatively correlated with HCC
recurrence. Interestingly, the expressions of miR-96 in non-tumor
tissues and miR-96 T/N ratio are the top ranked microRNAs that
are positively and negatively associated with HCC recurrence,
respectively. To understand how miR-96 plays biological roles
regarding HCC recurrence, it is important to identify target genes
of miR-96. In this study, we identified three genes, LRP6,
FOXO1A, and MAP2K1, that meet several criteria, such as, 1)
possessing cancer-related functions according to an ontology
database, 2) having microRNA target sites predicted by Target
Scan v.5.1 (www.targetscan.org/) in their 39-UTR, 3) inverse
correlation to miR-96 expression level in 146 samples (tumor and
non-tumor paired samples derived from 73 patients), (Table S2).
Furthermore, we also checked whether the miR-96 expression
data by DNA chips was reliable or not. The expression data of
Table 3. Recurrence-related principal components and correlated clinical factors.
Cox proportional hazard model
Rank Principal components hazard ratio p-value Notable correlated clinical factors p-value
1 PC3 0.9592 0.0171 serum, AFP* ,0.0001
serum, total-bilirubin* 0.0009
HBV antigen1 0.0020
2 PC16 0.9044 0.0207 platelet* 0.0040
Max diameter of tumor* 0.0135
T-factor (clinical)** 0.0202
3 PC1 1.0335 0.0244 serum, PIVKA-II* 0.0018
gender1 0.0398
4 PC4 1.0514 0.0246 HCV antibody1 0.0002
serum, AST* 0.0037
platelet* 0.0071
5 PC5 0.9591 0.0434 capsule formation (pathological)1 ,0.0001
presence of liver cirrhosis1 0.0042
ICG-R15* 0.0198
*: continuous variables,
**: category variables,
1: dichotonized variables.
The p-values of correlation between PCs and clinical factors were calculated by Pearson’s correlation analysis, Kruskal-Wallis test, and t-test for continuous, category, and
dichotonized variables, respectively.
doi:10.1371/journal.pone.0016435.t003
Figure 2. Three-dimensional scatter plot of PCA. The x-, y-, and z-
axes represent the top-3 ranked PCs (PC3, PC16 and PC1). The color
graduation scale from green, black to red represent short, intermediate,
and long recurrence-free survival, respectively. The closed circles, and
closed triangles correspond to complete and censored cases, respec-
tively. Patients with poor outcomes tend to be in the right-lower side
from this point of view, whereas patients with good outcomes tend to
be in left-upper side.
doi:10.1371/journal.pone.0016435.g002
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with that by DNA chip analysis (Figure S2).
Differentially expressed microRNAs
Differentially expressed microRNAs between T-miRs and N-
miRs are shown in Table S3, S4. Among 73 cases enrolled in this
study, 4 patients had macroscopically normal and pathologically
normal (n=1) or slightly fibrotic (n=3) liver tissues. We listed
differentially expressed microRNAs compared to these four normal
liver samples in Table S5. According to Table S3, S4, S5, miR-96
expression level was gradually elevated from normal liver, via non-
tumor liver tissues with accompanied chronic change, to tumor
tissues. We also listed differentially expressed microRNAs depend-
ing upon HBV/HCV status and tumor differentiation grade in
Table S6, S7, S8. Furthermore, using univariate Cox proportional
hazard model, we show microRNAs significantly associated with
HCC recurrence in subgroups categorized by HBV/HCV status
and tumor differentiation grade in Table S9, S10, S11, S12.
Discussion
In this study, we performed microRNA signature analysis and
developed a mathematical model to predict HCC recurrence in
patients within the Milan Criteria and with mild liver cirrhosis (i.e.,
Child-PughA/B). Todate,there aremanymicroarray-based studies
[18–21] that predict the outcomes of HCC patients. However, our
study is the first microarray-based study that focuses on a potential
population of patients for future salvage transplantation, and that
underwent liver resection and fulfill the Milan Criteria.
Clinical significance of HCC recurrence prediction for
patients within the Milan Criteria
HCC patients who satisfy the Milan Criteria and who have
sufficient liver function have two potential curative therapeutic
options: liver resection and orthotopic liver transplantation. However,
both options have advantages and disadvantages. Therefore, a
compromised option of liver resection plus salvage liver transplan-
tation seems reasonable. Even taking this option, recurrent tumors
must be detected in the early phase; otherwise, the benefits of salvage
transplantationwouldbediminished.Performingintensivefollow-ups
for all LR patients is not feasible. Therefore, a strategy of more
detailed follow-ups for patients with higher risk is necessary. This
prediction model will be a helpful tool to stratify these patients.
In this study, we obtained a relatively high prediction accuracy
(AUROC =0.8281) using a combined dataset of T-miRs and N-
miRs. Previously, many prediction models of HCC outcomes have
been reported. However, it is very difficult to compare the prediction
accuracy to other models, because the target population in the HCC
patients from this study was different from those in other reports.
Significance of microRNA profile in tumor and non-tumor
tissues
In this analysis, the prediction efficiency constructed using the
N-miRs dataset was better than that constructed using the T-
miRs. It is reasonable, because there are more recurrence-related
microRNAs in the N-miRs than in the T-miRs, according to
univariate CoxPH model analyses (Table 2). Previously, we
reported that co-existing cirrhosis was associated with a higher
Figure 3. Changes in time-averaged AUROCs and the number of variables used for prediction model construction. The prediction
models of HCC recurrence were constructed by the LOOCV method. The prediction accuracy for each model was evaluated by time-averaged AUROC
between 6 months and 5 years after the operation. The AUROC were different depending upon the sample tissues, the inclusion or exclusion of
PCA, and the number of variables used for constructing the prediction models. The best prediction accuracy was achieved when the model was
construct using top-twelve PCs data derived from all microRNA data (*: expression data of T-miRs and N-miRs, and T/N ratios). The best models using
T-miRs, N-miRs, and T/N ratios were obtained from the top-6 PCs, top-10 microRNAs, and top-12 PCs, respectively.
doi:10.1371/journal.pone.0016435.g003
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were stratified as low (n=37) and high (n=36) risk groups. The recurrence-free survival of the low risk group was significantly better than that of high
risk group by both a generalized-Wilcoxon test and the log-rank test.
doi:10.1371/journal.pone.0016435.g005
Figure 4. The AUROC changes of the best prediction model between 6 months and 5 years. In general, the prediction accuracy depends
upon the time point used to evaluate the prediction accuracy of the survival curve. Thus, we adopted AUROC as an index of prediction accuracy for
the survival curve. To cover both early and late recurrences, we calculated the AUROC between 6 months and 5 years. The black step graph shows
the changes in the AUROCs for the overall best prediction model (AUROC=0.8281). The red and blue step graphs represent the changes of AUROCs
of the best models using T-miRs and N-miRs datasets. The dotted lines of each color correspond to the AUROC for each step graph. This prediction
model using T-miRs can predict early recurrences better, whereas the model using N-miRs is better for late recurrences.
doi:10.1371/journal.pone.0016435.g004
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Criteria. This finding suggests that recurrences due to the
dissemination of primary tumors cells occur more often within
the initial few years after resection, and that late recurrences in
cirrhotic livers are likely attributable to multicentric de novo
carcinogenesis rather than dissemination of the primary tumor.
In this study, as shown in Figure 4, the T-miR models can predict
early recurrences better than late recurrences, whereas the N-
miR models can predict late recurrences better than early
recurrences. This finding suggests that the T-miR profile would
represent the malignant potential of primary tumors, and would
be associated with the presence of dissemination and the
consequent early recurrence, and that the N-miR profile would
reflect the accumulation of genome abnormalities (the ‘field
effect’) in the remaining non-cancerous liver cells, and would be
associated with multicentric late recurrence. Recently, several
papers have reported that an abnormal mRNA expression profile
in non-cancerous tissues is associated with HCC recurrence
[21,29,30]. Moreover, our previous clinical study showed that co-
existing cirrhosis correlated with the prognosis and recurrence of
HCC within the Milan Criteria [8]. Therefore, our finding
derived from the microRNA profile also supports the concept of
early and late recurrence that these previous reports have
proposed.
HBV infection, miR-96, and HCC Recurrence
The contribution analysis of microRNAs in the best prediction
model demonstrated that miR-96 in non-tumor tissues was the
most strongly associated with HCC recurrence. Previously, miR-
96 was identified as HBV infection-related microRNA[31]. In this
study, HBV infection and HBV-related PC3 were significantly
correlated with HCC recurrence, according to the univariate
CoxPH model (Table 2–3). Thus, it was reasonable that miR-96
was identified as a recurrence-related microRNA. In a supplement
analysis, we identified three genes, LRP6, FOXO1A, and
MAP2K1, that meet several criteria, described in result section.
Among them, the TargetScan predicted that FOXO1A has the
highest context score (an index for strength of bond between
mature microRNA and target sites to miR-96. Despite a strong
inverse correlation with miR-96 expression, LRP6 and MAP2K1
were predicted to have the relatively lower context scores than
FOXO1A. Taken together, FOXO1A would be the most
important HCC-related target gene of miR-96 microRNAs. This
finding was concordant with a previous report[32].
Time-averaged AUROCs as an index for survival
prediction accuracy
The CoxPH model can analyze data containing censored cases,
and can predict the survival curves of test cases using a baseline
survival curve bycalculating a hazard ratio. However, itis difficult to
evaluate the prediction accuracyofCoxPH models.Usually,analysts
stratify the patients according to the CoxPH model predictions, and
then compare the difference between groups using a generalized-
Wilcoxon or log-rank tests, or calculate the sensitivity, specificity, or
AUROCatagiven timepoint,such asthe2-yearsurvival.However,
the prediction accuracy of survival models depends upon stratifica-
tion criteria of the patients and the selection of a prediction time
point. Therefore, the prediction accuracy of survival models may be
Table 4. Contribution analysis of individual microRNAs in the overall best prediction model.
microRNAs positively associated with recurrence microRNAs negatively associated with recurrence
Rank miR name Tissue type Coefficient 95%CI{ miR name Tissue type Coefficient 95%CI{
1 miR-96 1 N 0.1349 (0.1259,0.1449) miR-96 T/N ratio 20.0865 (20.0941,20.0793)
2 miR-139-5p T/N ratio 0.0750 (0.0661,0.0850) miR-374b T/N ratio 20.0785 (20.0861,20.0710)
3 miR-139-5p T 0.0727 (0.0646,0.0815) miR-182 T/N ratio 20.0604 (20.0659,20.0549)
4 miR-126* T 0.0676 (0.0620,0.0737) miR-378 1 N 20.0561 (20.0612,20.0511)
5 miR-142-3p T 0.0673 (0.0599,0.0749) miR-193b T/N ratio 20.0543 (20.0600,20.0493)
6 miR-142-3p T/N ratio 0.0659 (0.0575,0.0754) miR-193b T 20.0539 (20.0596,20.0483)
7 miR-362-3p T 0.0596 (0.0538,0.0659) miR-214 T/N ratio 20.0535 (20.0585,20.0489)
8 miR-374b N 0.0563 (0.0499,0.0629) miR-125b 1 T 20.0522 (20.0569,20.0479)
9 miR-10b T 0.0548 (0.0482,0.0616) miR-125b T/N ratio 20.0521 (20.0565,20.0483)
10 miR-200a N 0.0544 (0.0486,0.0599) miR-99b T/N ratio 20.0517 (20.0564,20.0474)
11 miR-224 N 0.0530 (0.0466,0.0599) miR-1202 1 N 20.0515 (20.0584,20.0451)
12 miR-483-3p T 0.0529 (0.0459,0.0602) miR-18b T/N ratio 20.0513 (20.0590,20.0440)
13 miR-200a T 0.0527 (0.0477,0.0580) miR-365 T/N ratio 20.0511 (20.0573,20.0454)
14 miR-1202 T/N ratio 0.0507 (0.0441,0.0574) miR-100 T/N ratio 20.0506 (20.0559,20.0456)
15 miR-96 T 0.0484 (0.0423,0.0543) miR-365 T 20.0504 (20.0563,20.0445)
16 miR-665 T/N ratio 0.0474 (0.0413,0.0534) miR-210 T 20.0502 (20.0567,20.0440)
17 miR-1274a T/N ratio 0.0472 (0.0428,0.0518) miR-100 1 T 20.0500 (20.0547,20.0459)
18 miR-10b T/N ratio 0.0471 (0.0408,0.0533) miR-214 T 20.0491 (20.0544,20.0443)
19 miR-665 T 0.0469 (0.0411,0.0528) miR-378 1 T 20.0489 (20.0536,20.0444)
20 miR-1228 T/N ratio 0.0446 (0.0398,0.0500) miR-182 T 20.0476 (20.0534,20.0419)
Positive and negative coefficients indicates that higher and reduced expression of microRNA is associated with recurrence, respectively.
1: overlapped microRNAs in Table 2.
{: CI, confidence interval, calculated by 1000 times bootstrap resampling.
doi:10.1371/journal.pone.0016435.t004
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AUROC as a new evaluation index for the prediction efficiency of
the CoxPH model, which will be a robust index.
Future prospects regarding clinical application of
microarray technology
The MAQC project was initiated by the U.S. FDA, and the
second phase (MAQC-II) is currently in progress [33]. Its aims are
to assess the capabilities and limitations of microarray-based
predictive models, and to reach a consensus for the development
and validation of microarray-based predictive models for person-
alized medicine. Although reports from MAQC-II have not been
published yet, their reports will have a great impact on finalizing a
draft guideline of IVDMIA. Prior to finalizing the IVDMIA
guideline by the U.S. FDA, the FDA have already cleared two
microarray-based IVDMIA devices, MammaPrint
TM and Path-
work Tissue Origin Test
TM. In addition, OncoTypeDXH, a RT-
PCR-based IVDMIA, is widely used because health insurance
companies have adopted it as a criterion for insurance payment.
However, a microRNA-based IVDMIA device has not been
developed and approved yet. MicroRNA can be detected even in
formalin-fixed paraffin-embedded specimens [34], or remote fluid
samples such as blood[35], because of their stability. Therefore,
microRNAs are thought to be good biomarkers. The progress in
this study will be fundamental for the future application of
microRNA-microarray based IVDMIA into the clinical field.
However, our prediction model was only internally validated.
Therefore, prospective and external validation is necessary before
it is introduced to put microRNA microarray into practical use.
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value ,0.05 are listed. MicroRNAs (displayed in red) which
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(shown in blue) with hazard ratio less than 1 were associated with
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